SynthesisPloS one2020
Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: A systematic review and meta-analysis.
Synthesis in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06875336 (A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis), which is not on this map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentric Cohort and Biomarker Study for Improved Care of Patients with Extrapulmonary Tuberculosis
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Biomarker tests of progression from tuberculosis infection to disease: a systematic review.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- MicroRNAs as diagnostic biomarkers for Tuberculosis: A systematic review and meta- analysis.Frontiers in immunology · 2022Pooled it
- Evaluation of the Xpert MTB Host Response assay for the triage of patients with presumed pulmonary tuberculosis: a prospective diagnostic accuracy study in Viet Nam, India, the Philippines, Uganda, and South Africa.The Lancet. Global health · 2024Trial
- Blood transcriptomic signatures predict poor outcomes in drug-susceptible pulmonary tuberculosis in Brazil.American journal of respiratory and critical care medicine · 2026Article
- A single-cell atlas of peripheral immunity suggests immune subset attrition during tuberculosis dissemination.The Journal of international medical research · 2026Article
- Current and Emerging Diagnostic Approaches for Tuberculosis in People Living with HIV: Challenges and Future Perspectives.Tropical medicine and infectious disease · 2026Review
- Inflammatory biomarkers of asymptomatic and symptomatic tuberculosis.Nature communications · 2026Article
- Multidimensional cfRNA response modeling identifies a 5-gene pair signature for high-robust pulmonary tuberculosis diagnosis.iScience · 2026Article
- Neutrophil-specific transcriptomic profiling reveals a novel signature for active tuberculosis diagnosis.Microbiology spectrum · 2026Article
- PTBD: a machine learning-based non-invasive diagnostic model for pulmonary tuberculosis using large-scale blood transcriptomes.BMC biology · 2026Article
- Machine learning-based feature selection suggests circulating proteins as best at predicting and diagnosing tuberculosis inFrontiers in cellular and infection microbiology · 2026Article
- From gaps to progress: five-year global advances in the diagnosis of pediatric tuberculosis.Frontiers in pediatrics · 2026Review
- Host-response biomarkers for precision tuberculosis: from immune transcriptomic signatures to clinical risk stratification.Frontiers in cell and developmental biology · 2026Review
- Comparison of automated and manual mRNA enrichment to automated rRNA depletion for whole-blood RNA-sequencing.Scientific reports · 2025Article
- The Three-Gene Xpert Host Response Signature for Pediatric Tuberculosis Screening: A Prospective Diagnostic Accuracy Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Whom tuberculosis tests detect and why it matters: implications for diagnostic algorithms.The Lancet. Microbe · 2025Review
- Inflammatory Biomarkers of Asymptomatic and Symptomatic Tuberculosis.bioRxiv : the preprint server for biology · 2025Article
- Blood transcriptomic signatures predict poor treatment outcomes in drug-susceptible pulmonary TB in Brazil.medRxiv : the preprint server for health sciences · 2025Article
- CCR4⁺ memory Tregs and PD-1⁺ T cells as novel immunodiagnostic biomarkers for active tuberculosis.BMC infectious diseases · 2025Article
- Tuberculosis: An Update for the Clinician.Respirology (Carlton, Vic.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
introductionHost blood transcriptomic biomarkers have potential as rapid point-of-care triage, diagnostic, and predictive tests for Tuberculosis disease. We aimed to summarise the performance of host blood transcriptomic signatures for diagnosis of and prediction of progression to Tuberculosis disease; and compare their performance to the recommended World Health Organisation target product profile.
methodsA systematic review and meta-analysis of the performance of host blood mRNA signatures for diagnosing and predicting progression to Tuberculosis disease in HIV-negative adults and adolescents, in studies with an independent validation cohort. Medline, Scopus, Web of Science, and EBSCO libraries were searched for articles published between January 2005 and May 2019, complemented by a search of bibliographies. Study selection, data extraction and quality assessment were done independently by two reviewers. Meta-analysis was performed for signatures that were validated in ≥3 comparable cohorts, using a bivariate random effects model.
resultsTwenty studies evaluating 25 signatures for diagnosis of or prediction of progression to TB disease in a total of 68 cohorts were included. Eighteen studies evaluated 24 signatures for TB diagnosis and 17 signatures met at least one TPP minimum performance criterion. Three diagnostic signatures were validated in clinically relevant cohorts to differentiate TB from other diseases, with pooled sensitivity 84%, 87% and 90% and pooled specificity 79%, 88% and 74%, respectively. Four studies evaluated signatures for progression to TB disease and performance of one signature, assessed within six months of TB diagnosis, met the minimal TPP for a predictive test for progression to TB disease.
conclusionHost blood mRNA signatures hold promise as triage tests for TB. Further optimisation is needed if mRNA signatures are to be used as standalone diagnostic or predictive tests for therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.